Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 5/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | IKBKB | O14920 | 2/20 | 0.37 |
| ▸ | CHUK | O15111 | 2/20 | 0.37 |
| ▸ | TTK | P33981 | 2/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409487 | 0.84 | PTGS2 (0.45) | FYNPIM1 | |
| SCHEMBL2177585 | 0.83 | CA1 (0.48) | — | |
| SCHEMBL12409243 | 0.79 | TTK (0.57) | FYNADORA3TTK | |
| SCHEMBL12409489 | 0.78 | NTRK1 (0.43) | IKBKBCHUK | |
| SCHEMBL12409494 | 0.78 | FYN (0.43) | FYNPIM1MKNK1ADORA3TTK | |
| SCHEMBL12409282 | 0.73 | TTK (0.55) | POLBL3MBTL1ADORA3TTK | |
| SCHEMBL12409486 | 0.72 | CA1 (0.39) | FYN | |
| SCHEMBL12409483 | 0.71 | PI4KB (0.44) | CDK1 | |
| SCHEMBL8239625 | 0.70 | ADORA3 (0.56) | POLBL3MBTL1ADORA3TTKADRA2C | |
| SCHEMBL12409327 | 0.70 | FYN (0.47) | FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2567960-A2 | Imidazo[1,2-a]pyrazine compounds for treatment of viral infections such as hepatitis | Biofocus DPI Limited (GB) | 2013-03-13 | — | — | EP | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | CYP3A5, HAVCR2, CYP3A43 | FYN 3511/4885PIM1 429/4885POLB 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.